利拉鲁肽、二甲双胍、恩格列净三药联合治疗2型糖尿病肥胖患者对体质量、血糖及胰岛功能的影响  

Effects of Combination of Liraglutide,Metformin and Empagliflozin on Body Weight,Blood Glucose and Islet Function in Obese Patients with Type 2 Diabetes Mellitus

作　　者：陈文钰 CHEN Wenyu(Department of Endocrinology and Metabolism,Fuding Hospital,Fuding,Fujian Province,355200 China)

机构地区：[1]福建省福鼎市医院内分泌代谢病科,福建福鼎355200

出　　处：《糖尿病新世界》2023年第5期101-104,共4页Diabetes New World Magazine

摘　　要：目的探讨利拉鲁肽、二甲双胍与恩格列净三药联合治疗2型糖尿病(type 2 diabetes mellitus,T2DM)对患者体质量、血糖及胰岛功能的影响。方法选取2020年3月—2022年5月福建省福鼎市医院收治的126例T2DM肥胖患者,采用随机抽签法将其分为对照组与观察组,每组63例。对照组采用利拉鲁肽联合二甲双胍治疗,观察组给予利拉鲁肽、二甲双胍及恩格列净三药联合治疗,对比两组患者体质指数(BMI)、空腹血糖(FBG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)、胰岛β细胞功能指数(HOMA-β)、胰岛素抵抗指数(HOMA-IR)。结果治疗后,观察组FPG(7.37±0.71)mmol/L、2 hPG(10.53±1.09)mmol/L、HbAlc(8.32±1.23)%、BMI(25.35±2.12)kg/m^(2)均低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组HOMA-IR指数(2.41±0.29)低于对照组的(2.86±0.37),HOMA-β指数(70.03±11.29)高于对照组的(62.37±10.71),差异有统计学意义(P<0.05)。结论利拉鲁肽、二甲双胍及恩格列净联合治疗2型糖尿病肥胖患者的应用效果理想,可促进体质量下降,降低血糖水平,改善胰岛功能。Objective To investigate the effect of combined treatment of liraglutide,metformin and Empagliflozin on body weight,blood glucose and islet function in patients with type 2 diabetes(T2DM).Methods A total of 126 obese patients with T2DM admitted to Fuding City Hospital in Fujian Province from March 2020 to May 2022 were selected and randomly divided into a control group and an observation group,with 63 patients in each group.The control group was treated with liraglutide combined with metformin,while the observation group was treated with liraglutide,metformin,and entegliptin in combination.Comparison of body mass index(BMI),fasting blood glucose(FBG),2-hours postprandial blood glucose(2 hPG),glycosylated hemoglobin(HbA1c),homeostasis model assessment-β(HOMA-β)and homeostasis model assessment-insulin resistance(HOMA-IR)between two groups of patients.Results After treatment,FPG(7.37±0.71)mmol/L,2 hPG(10.53±1.09)mmol/L,HbA1c(8.32±1.23)%,and BMI(25.35±2.12)kg/m^(2) in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).After treatment,the HOMA-IR index in the observation group(2.41±0.29)was lower than that in the control group(2.86±0.37),HOMA-βindex(70.03±11.29)was higher than that of the control group(62.37±10.71),the difference was statistically significant(P<0.05).Conclusion The combination of rilalutide,metformin and engeglinide in the treatment of obese patients with type 2 diabetes mellitus has an ideal effect,which can promote the decline of body weight,reduce blood sugar levels and improve the function of pancreatic islets.

关 键 词：利拉鲁肽 二甲双胍 恩格列净 2型糖尿病 肥胖 血糖 胰岛功能 

分 类 号：R587.1[医药卫生—内分泌]